Sarepta Therapeutics Sees Unusually Large Options Volume (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the target of unusually large options trading activity on Thursday. Traders acquired 6,583 put options on the company. This is an increase of 246% compared to the average daily volume of 1,901 put options.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after acquiring an additional 117,904 shares during the period. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after purchasing an additional 285,100 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Sarepta Therapeutics by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock valued at $237,901,000 after buying an additional 10,343 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Trading Down 6.7 %

SRPT traded down $4.20 during trading on Thursday, reaching $58.27. 1,112,678 shares of the company’s stock were exchanged, compared to its average volume of 1,434,833. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a one year low of $57.14 and a one year high of $173.25. The firm has a fifty day moving average price of $99.40 and a two-hundred day moving average price of $114.66. The stock has a market capitalization of $5.65 billion, a PE ratio of 46.61 and a beta of 0.79.

Analyst Ratings Changes

SRPT has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft cut their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. HC Wainwright upgraded Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price target for the company in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. Finally, Needham & Company LLC cut their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $163.18.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.